You are here

  • Home
  • Archive
  • Volume 77, Issue 2
  • Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Smolen JS, Choe J, Prodanovic N, et al
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
Annals of the Rheumatic Diseases 2018;77:234-240.